Pain-Related Neuropeptide Substance P May Drive Cancer Progression Through TLR-4 Activation | Research

The takeaway

Substance P levels are elevated in cancer patients with pain and can upregulate TLR-4 in tumor cells, increasing proliferation, migration, and invasion — effects blocked by the NK-1R antagonist aprepitant.

TLR-4
receptor upregulated by substance P in tumor cells, increasing cancer aggressiveness

What the researchers found

Substance P was elevated in cancer patients with pain and upregulated TLR-4 expression in tumor cells via NK-1 receptors, increasing proliferation, migration, and invasion. Aprepitant blocked these effects.

Why it matters

This provides a molecular mechanism linking chronic pain to worse cancer outcomes — not just reduced quality of life but actual tumor progression. It suggests that NK-1R antagonists like aprepitant could serve dual roles as anti-nausea and anti-cancer agents.

The numbers in context

Substance P elevated in advanced cancer patients; SP promoted tumor growth and suppressed immunity via TLR-4 in vitro.

How the study worked

Serum samples from lung and breast cancer patients measured for substance P levels. Cell pharmacology experiments testing SP effects on TLR-4 expression, proliferation, migration, and invasion. Aprepitant (NK-1R blocker) used as a control.

Who was studied

Lung and breast cancer patients (serum analysis) and cancer/immune cell lines (in vitro)

What this study cannot tell us

In vitro experiments may not fully replicate in vivo tumor biology. Correlation between pain, SP levels, and cancer outcomes needs prospective clinical validation. Aprepitant's clinical anti-tumor efficacy hasn't been tested in trials.

How to read the evidence

Combines clinical observation (elevated SP in patients) with in vitro mechanistic evidence. Promising but requires clinical trial validation.

When this study was published

Published in 2020. The pain-cancer connection via neuropeptides remains an active research area.

The bigger picture

The connection between pain and cancer progression has been observed clinically but poorly understood mechanistically. This substance P pathway provides a biological explanation and, importantly, a druggable target using an already-approved medication.

Questions still open

Could routine use of NK-1R antagonists in cancer patients reduce tumor progression alongside managing pain?
Is substance P elevation specific to pain-related cancer progression or part of a broader inflammatory response?
Would aprepitant or similar drugs improve outcomes in a clinical cancer trial?

Common questions

Can pain actually make cancer worse?

This study suggests yes — through substance P, a neuropeptide released during pain that can directly stimulate tumor cells to grow, spread, and become more invasive.

What is aprepitant used for currently?

Aprepitant (brand name Emend) is FDA-approved to prevent nausea and vomiting from chemotherapy. This study suggests it might also have direct anti-cancer effects by blocking substance P's action on tumors.

Read the original research

Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4.

Pain medicine (Malden, Mass.), 21(12), 3443-3450

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Chao; Sun, Yunheng; Ouyang, Xueyan; Li, Jing; Zhu, Zhen; Yu, Ruihua; Wang, Li; Jia, Lin; Ding, Gang; Wang, Yaosheng; Jiang, Feng. (2020). Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4.. Pain medicine (Malden, Mass.), 21(12), 3443-3450. https://doi.org/10.1093/pm/pnaa265